Michael L. Main
Michael L. Main has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Anthony Magalski
7 shared publicationsBecky A. Morris
3 shared publicationsJonathan H. Goldman
3 shared publicationsLisa L. Kusnetzky
3 shared publicationsPaul A. Grayburn
Baylor University Medical Center, Dallas, Texas
3 shared publicationsTina R. Coggins
3 shared publications
Latest Publications
- 1 July 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (7) , 1039-1045
Safety of Ultrasound Contrast Agents in Patients With Known or Suspected Cardiac Shunts
- 1 July 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (7) , 1039-1045
Safety of Ultrasound Contrast Agents in Patients With Known or Suspected Cardiac Shunts
- 1 September 2010
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 23 (9) , 1007.e3-1007.e4
Contrast Enhanced Transesophageal Echocardiographic Guidance of Left Atrial Appendage Closure Device Implantation
- 1 September 2010
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 23 (9) , 1007.e3-1007.e4
Contrast Enhanced Transesophageal Echocardiographic Guidance of Left Atrial Appendage Closure Device Implantation
- 31 March 2009
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 6 (1) , 16-19
Safety and Risk-Benefit Profile of Microbubble Contrast Agents in Echocardiography
In patients with abnormal LV systolic function undergoing evaluation for LV remodeling, the use of ultrasound contrast agents reduces reader variability and increases accuracy compared with harmonic imaging
- 31 March 2009
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 6 (1) , 16-19
Safety and Risk-Benefit Profile of Microbubble Contrast Agents in Echocardiography
In patients with abnormal LV systolic function undergoing evaluation for LV remodeling, the use of ultrasound contrast agents reduces reader variability and increases accuracy compared with harmonic imaging
- 11 December 2008
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 8 (1) , 49-56
Ultrasound contrast agents: balancing safety versus efficacy
In October, 2007, the FDA issued a new 'black box' warning, several new disease state contraindications and a mandated 30-min post-procedure monitoring period for the ultrasound contrast agents Definity (perflutren lipid microsphere injectable suspension, Lantheus Medical Imaging, North Billerica, MA, USA) and Optison (perflutren protein type A microspheres for injectable suspension, GE Healthcare, Buckinghamshire, UK). These labeling changes were largely secondary to reports of 4 patient deaths, and approximately 190 other 'serious cardiopulmonary reactions' that were temporally related but not clearly causally attributable to Definity administration. Contrast agent use in the US plummeted in the immediate aftermath of this FDA action, with many hospitals, physician offices and outpatient imaging centers suspending contrast echocardiography altogether. This review will focus on the immediate response from the international physician community, new contrast agent safety data published within the past year, results of a special meeting of the FDA Cardio-Renal panel devoted to contrast agent safety in June 2008, recently issued revised product labeling for both agents and future prospects for contrast echocardiography.
- 11 December 2008
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 8 (1) , 49-56
Ultrasound contrast agents: balancing safety versus efficacy
In October, 2007, the FDA issued a new 'black box' warning, several new disease state contraindications and a mandated 30-min post-procedure monitoring period for the ultrasound contrast agents Definity (perflutren lipid microsphere injectable suspension, Lantheus Medical Imaging, North Billerica, MA, USA) and Optison (perflutren protein type A microspheres for injectable suspension, GE Healthcare, Buckinghamshire, UK). These labeling changes were largely secondary to reports of 4 patient deaths, and approximately 190 other 'serious cardiopulmonary reactions' that were temporally related but not clearly causally attributable to Definity administration. Contrast agent use in the US plummeted in the immediate aftermath of this FDA action, with many hospitals, physician offices and outpatient imaging centers suspending contrast echocardiography altogether. This review will focus on the immediate response from the international physician community, new contrast agent safety data published within the past year, results of a special meeting of the FDA Cardio-Renal panel devoted to contrast agent safety in June 2008, recently issued revised product labeling for both agents and future prospects for contrast echocardiography.
- 1 December 2008
- Published by Elsevier in The American Journal of Cardiology
- Vol. 102 (12) , 1742-1746
Acute Mortality in Hospitalized Patients Undergoing Echocardiography With and Without an Ultrasound Contrast Agent (Multicenter Registry Results in 4,300,966 Consecutive Patients)
- 1 December 2008
- Published by Elsevier in The American Journal of Cardiology
- Vol. 102 (12) , 1742-1746
Acute Mortality in Hospitalized Patients Undergoing Echocardiography With and Without an Ultrasound Contrast Agent (Multicenter Registry Results in 4,300,966 Consecutive Patients)
- 15 October 2006
- Published by Elsevier in The American Journal of Cardiology
- Vol. 98 (8) , 1110-1114
Contrast Administration Reduces Interobserver Variability in Determination of Left Ventricular Ejection Fraction in Patients With Left Ventricular Dysfunction and Good Baseline Endocardial Border Delineation
- 15 October 2006
- Published by Elsevier in The American Journal of Cardiology
- Vol. 98 (8) , 1110-1114
Contrast Administration Reduces Interobserver Variability in Determination of Left Ventricular Ejection Fraction in Patients With Left Ventricular Dysfunction and Good Baseline Endocardial Border Delineation
- 1 August 2006
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 19 (8) , 1038-1044
Pulmonary Hemodynamic Effects of Dipyridamole Infusion in Patients with Normal and Elevated Pulmonary Artery Systolic Pressure Receiving PB127
- 1 August 2006
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 19 (8) , 1038-1044
Pulmonary Hemodynamic Effects of Dipyridamole Infusion in Patients with Normal and Elevated Pulmonary Artery Systolic Pressure Receiving PB127